Haishi Wu

Haishi Wu

Auto-generated profile, based on publicly available information

Haishi Wu

Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2023 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
NGNa Gao
Na Gao
GGGuiwen Guan
Guiwen Guan
GXGanlin Xu
Ganlin Xu
HWHaishi Wu
Haishi Wu
CXChan Xie
Chan Xie
ZGZhi-Liang Gao
Zhi-Liang Gao

19 March 2025 in Virology Journal
Verified
Journal Article
Open access
PDF file
NGNa Gao
Na Gao
HWHaishi Wu
Haishi Wu
BLBin Li
Bin Li
HYHuiying Yu
Huiying Yu
LWLili Wu
Lili Wu
ZGZhi-Liang Gao
Zhi-Liang Gao
It is unclear whether nucleos(t)ide analogs (NUCs) continuation provides clinical benefits following HBsAg seroclearance with pegylated interferon (PEG-IFN)-based therapy. This study aims to investigate the role of NUCs continuation in HBsAg seroreversion. Patients who experienced serum HBsAg loss after PEG-IFN-based therapy were enrolled and followed up for 96 weeks. Propensity score matching (PSM) was performed using a 1:1 ratio to adjust for the associated factors. A multivariate logistic regression analysis was used to determine the factors associated with HBsAg seroreversion. In total, 220 patients with HBsAg seroclearance were divided into NUCs (n = 54) and non-NUCs (n = 166) consolidation therapy groups. At week 96, the HBsAg seroreversion (12/54 vs. 31/166, P = 0.709) and virological relapse (2/54 vs. 10/166, P = 0.759) rates were similar in the NUCs and non-NUCs groups. After PSM, HBsAg seroreversion (12/53 vs. 13/53; P = 1.000) and virological relapse (2/53 vs. 4/53; P = 0.674) rates were not significantly different between the two groups. Serum hepatitis B surface antibody titer (odds ratio, 0.388; 95% confidence interval, 0.245–0.616; P < 0.001) was found to be associated with HBsAg seroreversion, while NUCs continuation was not related to HBsAg seroreversion. NUCs continuation is not associated with a lower risk of HBsAg seroreversion in patients with serum HBsAg loss following PEG-IFN-based therapy.

31 May 2025 in Virology Journal
Verified
Journal Article
Open access
PDF file
NGNa Gao
Na Gao
HWHaishi Wu
Haishi Wu
BLBin Li
Bin Li
HYHuiying Yu
Huiying Yu
LWLili Wu
Lili Wu
ZGZhi-Liang Gao
Zhi-Liang Gao